This Month’s Focus: Nasal Delivery, Nebulizers and Soft Mist Inhalers
Nasal and trans-nasal lung deposition of aerosols
With recent advances in devices and formulations, many more conditions are expected to be treatable with nasal delivery. Trans-nasal pulmonary administration remains in its infancy but is poised to grow as evidenced by its rapid adoption to routine use in many intensive care units worldwide. We believe the next decade should see significant advances in both.
Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
In this opinion article, the authors pose the question, “Can we improve accessibility and affordability of orally inhaled therapies while protecting incentives for the development of innovative products?” and invite readers to join a discussion.
Back Page: Inhaler digital sensors help correlate reductions in power plant emissions and improvements in asthma
Researchers used digital inhaler sensors to study frequency of asthma rescue medication usage and emergency room visits following changes in emissions from coal-fired power plants in Louisville, Kentucky.
Cross-industry organizations: The Aerosol Society and Drug Delivery to the Lungs 2020
An update on recent activities including the establishment of the Centre for Doctoral Training in Aerosol Science and initial plans for DDL2020, which will be replaced by The Christmas Lectures.
Cascade impactor stage groupings: Poor decisions from degraded data
Particle engineering approaches for dry powder inhalers
Cross-industry organizations: Respiratory Drug Delivery (RDD)
Back page: Antibiotics in infancy tied to allergies in childhood
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
June: Nasal Delivery/Nebulizers
August: Particle Characterization
1155 Northland Drive
St. Paul, MN 55120
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.